- Profile and Organization
- Our Commitments
- Societal Needs
- Bayer Employees
- Bayer Worldwide
- Corporate Compliance
- Corporate Governance
- Board of Management
- Supervisory Board
- Contact Us
Group to take comprehensive range of portfolio, efficiency and structural measures
Bayer to strengthen core life science businesses while significantly enhancing productivity and profitability
Group plans to exit Animal Health business, the Consumer Health brands Coppertone™ and Dr. Scholl’s™, and sell its 60-percent interest in Currenta, a site services provider in Germany /// Efficiency and structural measures set to enhance competitiveness and generate annual contributions of 2.6 billion euros as of 2022 including the expected synergies from the Monsanto acquisition /// A portion of the contributions to be reinvested in core businesses /// Total one-time costs expected at a factor of 1.7 times annual contributions /// Core earnings per share expected to increase by around 1 euro to 6.80 euros in 2019, with a target of around 10 euros in 2022 /// EBITDA margin before special items set to amount to over 30 percent in 2022 /// Efficiency and structural measures expected to result in the reduction of around 12,000 of 118,200 jobs worldwide, a significant number of them in Germany
Media Conference Call
Bayer’s corporate strategy, financial targets and capital allocation priorities will be outlined at the
You will find the key statements on » Twitter
Cautionary Statements Regarding Forward-Looking Information
This information contains forward-looking statements. A forward-looking statement is any statement that does not relate to historical facts and events, but rather reflects Bayer’s current beliefs, expectations and assumptions regarding the future. This applies, in particular, to statements in this presentation on revenue growth, including product introductions and peak sales potential, synergies, especially in relation to the acquisition and integration of Monsanto Company, portfolio adjustments, cost reduction, financial targets and earnings, cash flow generation, deleveraging and other similar statements relating to future performance, including with respect to the markets in which Bayer is active.
Although the forward-looking statements contained in this presentation are based upon what Bayer’s management believes are reasonable assumptions, they necessarily involve known and unknown risks and uncertainties that could cause actual results and future events to differ materially from those anticipated in such statements. Forward-looking statements are not guarantees of future performance and undue reliance should not be placed on them. Bayer undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.
For more information on factors that could cause actual results and future events to differ from those anticipated in forward looking statements, please refer to the factors discussed in Bayer’s public reports which are available on the Bayer website at https://www.investor.bayer.de/en/reports/annual-reports/overview, including in the Annual Report 2017 under the caption “Report on Future Perspectives and on Opportunities and Risks”.